[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

4D Molecular Therapeutics Inc (FDMT)

4D Molecular Therapeutics Inc (FDMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 889,428
  • Shares Outstanding, K 55,244
  • Annual Sales, $ 85,210 K
  • Annual Income, $ -140,110 K
  • EBIT $ -197 M
  • EBITDA $ -197 M
  • 60-Month Beta 2.73
  • Price/Sales 10.87
  • Price/Cash Flow N/A
  • Price/Book 2.15

Options Overview Details

View History
  • Implied Volatility 92.50% (-10.58%)
  • Historical Volatility 82.88%
  • IV Percentile 2%
  • IV Rank 4.40%
  • IV High 545.35% on 01/08/26
  • IV Low 71.64% on 07/22/26
  • Expected Move (DTE 27) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.60
  • Today's Volume 80
  • Volume Avg (30-Day) 110
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 6,240
  • Open Int (30-Day) 5,419
  • Expected Range 15.83 to 15.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.03
  • Number of Estimates 4
  • High Estimate $-0.99
  • Low Estimate $-1.07
  • Prior Year $-1.01
  • Growth Rate Est. (year over year) -1.98%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.39 +68.58%
on 07/29/26
16.93 -6.50%
on 08/19/26
+4.45 (+39.16%)
since 07/21/26
3-Month
8.37 +89.13%
on 06/11/26
16.93 -6.50%
on 08/19/26
+7.14 (+82.16%)
since 05/21/26
52-Week
5.97 +165.16%
on 09/02/25
16.93 -6.50%
on 08/19/26
+8.98 (+131.09%)
since 08/21/25

Most Recent Stories

More News
4D Molecular Therapeutics: The Runway Math Doesn't Add Up Despite the Investor Day Optimism

Barchart Research What to Expect from FDMT Earnings FDMT Generated August 14, 2026 Current Price $12.19 EPS Estimate $$-1.04 Consensus Rating Moderate Buy Average Move 5.31% 4D Molecular Therapeutics:...

FDMT : 15.83 (-1.68%)
4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 15.83 (-1.68%)
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

Completed enrollment for 4D-150 4FRONT-2 wet AMD Phase 3; topline data expected in H2 2027  4D-150 4FRONT-1 Phase 3 topline data expected in Q2 2027 Presented positive 2-year data from 4D-150 PRISM...

FDMT : 15.83 (-1.68%)
4D Molecular Therapeutics' Gene Therapy Pipeline Faces Its First Real Commercial Scrutiny

Barchart Research What to Expect from FDMT Earnings FDMT Generated August 7, 2026 Current Price $10.76 EPS Estimate $$-1.04 Consensus Rating Moderate Buy Average Move 5.31% 4D Molecular Therapeutics' Gene...

FDMT : 15.83 (-1.68%)
4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population

After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden reduction through 2 years  4D-150 continues to be well tolerated...

FDMT : 15.83 (-1.68%)
4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 15.83 (-1.68%)
4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists

EMERYVILLE, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 15.83 (-1.68%)
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital

EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted...

FDMT : 15.83 (-1.68%)
HTGC : 17.13 (+0.59%)
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD

4FRONT-2 global enrollment completed approximately 4 months ahead of initial projections 4FRONT-2 over-enrolled (anticipated N>500), with final patient randomization expected in Q3 2026, reflecting...

FDMT : 15.83 (-1.68%)
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker

ALAMEDA, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting...

FDMT : 15.83 (-1.68%)
VANI : 1.3800 (-2.13%)

Business Summary

4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated viruses vectors. It offers a portfolio of gene therapy product candidates focusing on the ophthalmology, cardiology and pulmonology therapeutic areas....

See More

Key Turning Points

3rd Resistance Point 18.30
2nd Resistance Point 17.60
1st Resistance Point 16.72
Last Price 15.83
1st Support Level 15.14
2nd Support Level 14.44
3rd Support Level 13.56

See More

52-Week High 16.93
Last Price 15.83
Fibonacci 61.8% 12.74
Fibonacci 50% 11.45
Fibonacci 38.2% 10.16
52-Week Low 5.97

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.